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The BCG vaccine is known to impart nonspecific immunological benefits alongside conferring protection to
tuberculosis in endemic regions. It is also known to protect against bladder cancer and other respiratory tract
infections. During the coronavirus disease 2019 (COVID-19) pandemic, the BCG vaccine has gained attention due
to its role in conferring protective immunity. We demonstrate the potential immunological protective mecha
nisms that play a role against COVID-19. We conduct a global assessment of the countries that have the highest
and lowest mortality rates determined by an a priori methodology. Lastly, we discuss the potential limitations of
incorporating BCG vaccines as potential strategies against COVID-19 and provide recommendations regarding
their use in ongoing and future epidemics.

1. Introduction
Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated Myco
bacterium bovis that was developed to combat Tuberculosis (TB) in
fections in the early 20th century [1,2]. One of the most widely used
vaccines globally, BCG, is administered at once at birth with immune
correlates of protection suspected to extend to adulthood [3]. Countries
like France, Germany, and Spain stopped mass BCG immunization as the
prevalence of TB decreased in these countries. In contrast, countries like
China, Russia, and Ukraine continue to administer BCG mass immuni
zation [1]. BCG is the only licensed vaccine for TB and is traditionally
administered at the time of birth. Evidence supports that BCG vaccina
tion is effective in preventing adult pulmonary tuberculosis (TB), which
is caused by Mycobacterium tuberculosis. Numerous prospective trials
and recent retrospective studies show that BCG provides immunity
against pulmonary TB for up to 50 years [3]. The activation of the
bystander B and T cells independent of antigens could be one of the
mechanisms by which BCG provides non-specific immunity, known as
heterologous immunity [4]. Secondly, the innate immune cells could be

activated and reprogrammed by BCG, establishing trained innate im
munity [4]. The hypothesis that BCG vaccination provides heterologous
immunity against COVID-19 is currently under investigation. We find
that COVID19 mortality may be associated with BCG vaccination as
countries like South Korea, Japan, being ones with an active BCG
vaccination policy, have a lower COVID-19 mortality rate than countries
with no active BCG vaccination policy such as the USA and Italy.
Whether BCG, a century-old vaccine that was first used in 1921, is one of
the contributing factors to reduced COVID-19 mortality is a subject of
interest. Our ecological study not only sheds light on the differences of
BCG vaccinations on COVID-19 mortality but also how the vaccine may
confer with protective immunity against other pathogens [4].
2. Materials and methods
An a-priori methodology was used to identify the top ten and bottom
ten countries according to the death rate (Fig. 1). The death rate was
taken as the relative number of COVID-19 deaths within a population
per unit of time. The daily counts of COVID-19 cases and deaths globally
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Fig. 1. 1 a and b. Global assessment of countries according to death rate per population and BCG vaccination policies. An a priori methodology was established to
tabulate countries according to descending death rates per population. The top and bottom 10 countries were identified and the BCG vaccination policies
were identified.
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were obtained by the World Health Organization Coronavirus disease
situation dashboard. For every country until 31 March, which had at
least 100 confirmed cases, a tabulated list was arranged with the total
deaths within that population from day X. Day X was taken as the day at
which at least 100 confirmed cases were recorded. Defined as day Y, the
total deaths were then identified in the next 30 days since day X. The
death rates were arranged in descending order, and countries greater
than 5,000,000 km2 were further analyzed by state or province. The
states or provinces whereby the death rates per population were in the
top or bottom ten were also taken as “countries” for our study.

of measles, mumps, and rubella (MMR) vaccine in COVID-19.
Senoo et al. reviewed the morbidity and mortality rates among the
Organization for Economic Co-operation and Development (OECD) at
different stages of the pandemic and the differential impact of BCG
implementation [6]. The methodology had the limitation of not ac
counting for different stages across the pandemic but was able to
demonstrate similar findings to our study in favor of BCG vaccination
policies and the trends of the COVID-19 pandemic [6]. Another study
conducted by Pathak et al. accounted for different stages of the
pandemic at three different time points with findings similar to ours
showing correlation of BCG vaccination policies with lower COVID-19
mortality rates [7]. Pandita et al. and Mohapatra et al. note the lower
incidence of COVID-19 in countries with routine vaccination programs,
citing nonspecific effects (NSEs) of BCG vaccination in TB-endemic
countries [8,9]. However, identify the difficulty of ascertaining BCG
vaccination policies on the dynamics of the COVID-19 pandemic citing
the multifactorial nature of the early stages and minimal accounting of
confounding factors [10,11]. A study reviewed the contribution of
confounding factors with the incidence of TB being a significant
contributor explaining the differences in the COVID-19 mortality burden
[12]. Further, a cohort of 6,201 healthcare workers (HCWs) of whom
29.6% had been vaccinated for BCG and 68.9% had not been. There was
a significant correlation among a history of BCG vaccination of HCWs
with lower incidence, seroconversion assessed by anti-SARS-CoV-2 IgG
levels as well as lower self-reported symptoms [13].

3. Results
The top 10 countries were identified according to the death rates per
population. Deaths were obtained in the first 30 days after at least 100
confirmed cases were identified before March 31, 2020. The top 10
countries had BCG recommendations for only specific groups. However,
the bottom ten countries had current national BCG vaccination policies
for all at birth. The findings are summarized in Fig. 1.
Further, the top ten and bottom ten countries were screened for the
incidence of tuberculosis (TB), education index, and percentage of the
population aged 65 and above. The top 10 countries had a lower inci
dence of TB, with only three countries with an incidence of >5 per
100,000 people, including Spain, Belgium, and the United Kingdom,
identified in Table 1. The overall poverty headcount ratio was low in the
top 10 countries and was in direct correlation with the lower rates of
incidence in the countries. All the countries in the top 10 had BCG na
tional policies for specific groups. The education index was high in the
top 10 countries, between 0.790 till 0.894. However, 16–25% of the
total population in the top 10 countries was aged 65 years and above.
Approximately 90–98% of the children aged 12–23 months were given
the measles vaccine in 2019.
The bottom 10 countries had BCG vaccination policies for all that
corroborate with the higher incidence of TB, ranging from 12 to 554 per
100,000 people, tabulated in Table 2. The poverty headcount ratio was
variable in the bottom ten states/nations. The incidence of TB was
higher in correlation to the poverty index. The education index was
consistently lower than in the top 10 countries except for South Korea.
The bottom 10 countries had fewer percentages of the population aged
65 and above except South Korea and Russia. The other countries within
the bottom 10 had a 4–11% population in the older age groups. With the
exceptions of Pakistan and the Philippines, the immunization of measles
was comparable to the top 10 countries.

4.1. Innate immunity in SARS-CoV-2
Davids et al. conducted a study in Africa to compare 2 BCG strains,
namely BCG Japan and BCG Denmark. It showed that a more robust
proliferation of CD4+ and CD8+ T cells was induced by BCG Japan.
Also, there was a lower secretion of Th2 cytokines (IL-4) and higher
secretion of Th1 cytokines (interferon-γ, TNF-α, and IL-2) by BCG Japan
compared with BCG Denmark [14]. Another study conducted in Mexico
showed that BCG Japan induced higher levels of IL-1α, IL-1β, IL-6, and
IL-24 compared to BCG Denmark. These studies suggest that BCG Japan
produces multiple types of inflammatory cytokines in peripheral blood
lymphocytes and is more efficient for the same when compared to BCG
Denmark [15].
4.2. Immune correlates of protection
After intradermal injection of BCG vaccination, local neutrophils,
macrophages, and dendritic cells at the site of inoculation begin the
immune response through the interaction of different pattern recogni
tion receptors such as toll-like receptors-2 (TLR-2) and 4 (TLR-4) with
pathogen-associated molecular patterns (PAMPs), including peptido
glycan, arabinogalactan, and mycolic acids present on the bacterium cell
wall. Other cell receptors that can recognize BCG PAMPs include
nucleotide-binding oligomerization domain (NOD)-like receptors (such
as NOD2), found in the cytoplasm of innate immune cells. Besides, Ctype lectins (such as DC-specific intercellular adhesion molecule-3grabbing non-integrin) participate in the recognition and internaliza
tion of BCG, which results in dendritic cells maturation and migration
and expression of costimulatory molecules such as CD40, CD80, CD83,
and CD86 [16]. Moreover, antigen 85, present in BCG’s cell wall,
stimulates the production of proinflammatory factors such as TNF-alpha
(tumor necrosis factor-alpha), interleukin (IL) 1-beta, and IL-6, which
promotes the activation of immune cells.

4. Discussion
Poverty is widely recognized as a contributing factor to TB, with a
higher global prevalence in South-East Asia (44%), Africa (24%), and
the Western Pacific (18%). Poverty, housing quality, and undernutrition
are frequently cited as determinants for higher incidences of TB both
among and within these countries. Over 10 million cases were diagnosed
in 2018, and the 153 countries are administering BCG vaccine as stan
dard practice in childhood immunization programs, the coverage of
which is >90% in 113 countries [5]. Previously, studies have reviewed
the incidence of COVID-19 cases in countries where BCG was mandated
and compared with countries that did not. While there may be ecological
bias, our findings were standardized by taking the death rates in the first
wave of the pandemic. While it is certain that the testing rates and the
rates of incidence were higher in larger countries with better health
infrastructures, we reviewed the confirmed cases and deaths in the first
30 days, thereby accounting for the differences in such factors. BCG
vaccination is recommended in countries in TB-endemic countries, and
clinical trials are underway to determine the efficacy of BCG on the
immune system when immunized later in life. The rates of measlesimmunized children were comparable across the top and bottom ten
countries, with recent attention given to the potential protective effects

4.3. Trained immunity
In 2011, Netea et al. proposed for the first time the concept of
“trained immunity,” described as a less specific response to a secondary
infection mediated by innate immune cells (monocytes/macrophages
and NK cells), either to the same pathogen or a different one (cross3
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Table 1
Top 10 countries selected by the Day Y deaths rate. Only countries with more than 1000 deaths till day Y were further screened for deaths per population. The incidence
of tuberculosis (per 100,000 people) was calculated in 2018 by the World Health Organization. The education index is calculated using Mean Years of Schooling and
Expected Years of Schooling, reported by the United Nations Development Programme as of 15 December 2013. The population, aged 65 and above, was reported by
the World Bank based on estimates of age/sex distributions by the United Nations Population Division’s World Population Prospects in 2019. The percentage of
children aged 12–23 months who were given measles vaccine was reported by WHO and UNICEF in 2019. *A State (note the capital “S”) is a self-governing political
entity that can be used interchangeably with a country. A nation, however, is a tightly-knit group of people who share a common culture. The top 10 “ countries” also
include states or provinces for countries with an area greater than 5,000,000 km2.
Top 10
countries

Da X
=
100th
case
day

Day Y
= 30
days
from
X (Y
=X+
30)

Number of
cases on
Day Y

Number
of deaths
till date Y

New Jersey

Mar 16

67,874

3156

Connecticut

Mar 19

16,464

New York
Michigan

Mar 7
Mar 19

Louisiana

Mar 15

Spain
Belgium
Italy

Mar 3
Mar 7
Feb 24

Netherlands
United
Kingdom

Mar 7
Mar 6

Apr
15
Apr
18
Apr 6
Apr
18
Apr
14
Apr 2
Apr 6
Mar
25
Apr 6
Apr 5

Population
(in
millions)

Day Y
deaths per
population*

Incidence
of TB per
100,000
people*

Poverty
headcount
ratio at $1.90
a day (% of
the
population)

Education
Index*

Population
aged 65 and
above (% of
the total
population)

Immunization
of measles (% of
children ages
12–23 months)

8.88

355

3

1.0

0.890

16

90

1086

3.57

304

3

1.0

0.890

16

90

1,306,089
25,246

4758
2308

19.45
9.99

244
231

3
3

1.0
1.0

0.890
0.890

16
16

90
90

21,951

1013

4.65

217

3

1.0

0.890

16

90

102,136
19,691
69,176

9053
1447
6820

46.72
11.42
60.43

193
126
112

9
9
7

0.9
0.1
2.0

0.794
0.812
0.790

20
19
23

98
96
94

17,851
41,907

1766
4313

17.23
66.49

102
64

5
8

0.1
0.1

0.894
0.860

20
16

94
91

protection), and independent of T and B cell responses [17]. It has been
demonstrated that after BCG vaccination, peripheral blood monocytes
display a rise in H3K4me3 histone modification (epigenetic reprog
ramming), triggering proinflammatory cytokine production (through
the transcription of the genes tnfα, il6, and tlr4), and improving
microorganism recognition by pattern recognition receptors (PRRs)
such as TLRs, C-type lectins receptors, NOD-like receptors, and RIG-Ihelicases. When these ”trained monocytes“ are subsequently exposed
to a second infection, the microorganism would be recognized by these
PPRs, driving to a cytokine burst [16,18].

during 1–3 years [21,22]. Innate and adaptive immune responses are
part of the BCG mechanism of action. TURBT causes urothelial damage;
in these areas, BCG bacteria adhere to the damaged bladder mucosa,
where, following its binding via α5β1 integrin receptors, it enters the
malignant urothelial cell. After internalization, a primary innate im
mune response involves cytokine release of TNF-α, IFN-γ, IL-2, IL-6, IL-8,
and IL-12; this release activates neutrophils, T lymphocytes, BCGactivated killer cells, and natural killer cells, eliminating malignant
urothelial cells with the internalized BCG bacteria. After induction
therapy, BCG-induced immune response slowly decreases. Thus the need
for maintenance therapy to heighten the immune cell response and
cytokine levels [22].
BCG vaccine, recommended by WHO, is the widely used vaccine for
protection against pulmonary TB. The efficacy of the vaccine was tested
in several prospective and retrospective trials. A case-control study in
the UK consisting of 54,239 children aged 14–15 years reported 77%
vaccine efficacy in preventing pulmonary TB incidence until up to 15
years after getting the BCG vaccine [23]. Two recent independent
retrospective studies from Norway and the UK also supported a signifi
cant vaccine efficacy for at least 20 years against pulmonary TB. In
addition to TB, the BCG vaccine was found to show protection against
infections like influenza A virus, pandemic influenza (H1N1), and other
acute respiratory tract infections, both upper and lower. Leentjens et al.
reported that people with BCG vaccination developed a significantly
higher hemagglutinin (HI) antibody to protect against H1N1 influenza
[24]. Another study reported a significant reduction in the incidence of
ALRI by 17% to 37% after receiving the BCG vaccine [25]. The BCG
vaccine has also shown protection against ARTIs compared to unvacci
nated counterparts, especially among the older population [26].
Furthermore, studies have shown a decrease in mortality rate from
pneumonia in children who were vaccinated with the BCG vaccine. A
significant reduction in hospitalization due to respiratory infections was
also observed [27,28].

4.4. Heterologous immunity
BCG causes a Th1-type proinflammatory cytokine production and
activates innate immunity arbitrating antimycobacterial responses. Still,
other T-cell populations could also respond in a heterologous manner.
Kleinnijenhuis et al. measured BCG vaccination’s effect on heterologous
Th1 and Th17 responses showing C. Albicans and S. aureus boosted IL17 and IL-22 production at two weeks and one-year post-immunization
in BCG-vaccinated adults; compared with the control group, CD8+
Bordetella pertussis-specific T cells were found in BCG-vaccinated HIVexposed but uninfected infants in South Africa [19]. Due to BCG
vaccination, the heterologous T-cell response might improve trained
innate immunity even after multiple weeks of immunization and provide
heterologous protection from infections once trained innate immunity
fades [20].
4.5. BCG vaccination efficacy in other illnesses
Bladder cancer therapy, specifically the non-muscle-invasive forms
of bladder cancer (NMIBC), uses BCG bacterial intravesical instillation
following transurethral resection of tumors (TURBT) as a standard
treatment. BCG therapy usually involves an induction regimen consist
ing of a 6-week course of 2–19 × 108 colony forming units (CFUs) of
BCG in normal saline to be instilled through a catheter into an empty
bladder, 2–3 weeks after the TURBT, followed by a maintenance treat
ment of intravesical BCG instillations for six weeks, every three months

5. Key message
The use of the BCG vaccine varies globally, with some countries still
4
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Table 2
Bottom 10 countries selected by Day Y deaths rate. Only countries with more than 100 deaths till day Y were further screened for deaths per population. The incidence
of tuberculosis (per 100,000 people) was calculated in 2018 by the World Health Organization. The education index is calculated using Mean Years of Schooling and
Expected Years of Schooling, reported by the United Nations Development Programme as of 15 December 2013. The population, aged 65 and above, was reported by
the World Bank based on estimates of age/sex distributions by the United Nations Population Division’s World Population Prospects in 2019. The percentage of
children aged 12–23 months immunized with measles was reported by WHO and UNICEF in 2019.
Bottom 10
countries

Da X
=
100th
case
day

Day Y
= 30
days
from
X (Y =
X+
30)

Number
of cases
on Day Y

Number
of deaths
till date Y

Population
(in
millions)

Day Y
deaths per
population*

Incidence
of TB per
100,000
people*

Poverty
headcount
ratio at $1.90
a day (% of
the
population)

Education
Index*

Population
aged 65 and
above (% of
the total
population)

Immunization of
measles (% of
children ages
12–23 months)

Pakistan
India
South
Korea
Egypt
Indonesia
Argentina
Russia
Philippines
Colombia
Morocco

Mar 17
Mar 15
Feb 20

Apr 16
Apr 14
Mar
21
Apr 15
Apr 14
Apr 20
Apr 18
Apr 14
Apr 19
Apr 22

6505
10,363
8799

124
377
102

212.22
1352.62
51.64

0
0
1

265
199
66

3.9
21.2
0.2

0.372
0.473
0.865

4
6
15

75
95
98

2350
4557
2839
36,793
4932
3439
3209

178
399
132
313
315
153
145

98.42
267.66
44.49
144.48
106.65
49.65
36.03

1
1
2
2
2
3
4

12
316
27
54
554
33
99

1.3
7.2
0.7
0.1
6.1
4.5
1.0

0.573
0.603
0.783
0.780
0.610
0.602
0.468

5
6
11
15
5
9
7

95
88
94
98
67
95
99

Mar 16
Mar 15
Mar 21
Mar 19
Mar 15
Mar 20
Mar 23

further BCG trials to be carried out to uncover the real answer to the
question unless the trials are carried out by adequately informing their
participants about the risk of local and systemic complications from BCG
vaccination.

having mandatory vaccine administration. At the same time, some
terminated the mandatory administration policy, and some never had
such a policy. Studies have shown that countries with a mandated BCG
vaccine policy have a flatter curve and fewer deaths than those without
such policy [29]. COVID-19 mortality was noted to be markedly higher
in countries where BCG vaccination is not widely administered or is
given only to high-risk groups or where it was discontinued more than
20 years ago [1]. COVID-19 mortality in different socially similar Eu
ropean countries was observed, indicating that every 10% increase in
the BCG index was associated with a 10.4% reduction in COVID-19
mortality [1]. A study analyzing COVID-19 mortality in the first
month of the pandemic surge found that countries with a BCG index of
almost zero, like the Netherlands and Italy, had a high mortality rate of
75–100 per 100 million compared to the countries with a BCG Index
close to 1.0, such as Ukraine and Lithuania, whose mortality rate was
close to zero and close to 12.5 respectively [1]. The consistent associa
tion between BCG vaccination and reduced severity of COVID-19
observed is remarkable and hence warrants further studies and trials
to be conducted.
Heterologous effects of adaptive immunity and trained innate im
munity are the two immunological actions that have been described as
the protective host response of BCG against COVID 19 [30]. To prove the
benefits of BCG, clinical trials are underway. Most of these trials aim to
recruit frontline health workers to demonstrate the effects of BCG on
total case occurrence and the severity of COVID 19 [31]. The current
epidemiological data indicates that countries with very low no. of total
deaths, including South Asian Association for Regional Cooperation
(SAARC) countries, adopted a mandatory BCG vaccination program
[32]. In contrast, countries with a higher number of cases didn’t have
widespread BCG vaccination [32]. However, discrepancies exist in the
above epidemiological data, and mortality due to COVID 19 depends on
a no. of factors like age, comorbid conditions of patients, available
health infrastructure of the region. Although case fatality could be a fair
comparison of COVID-19 related deaths, it is challenging to get the exact
no. or estimate of people infected with COVID-19 in a particular region
as it depends on the testing facility availability, resources, climate of
that region, and proportion of symptomatic to asymptomatic cases.
Further, the strict lockdown measures, mandatory social distancing, and
mask-wearing may have mitigated the spread of COVID-19 in a region.
Also, there might be other unknown confounding factors that need
consideration before making a strong conclusion regarding the effect of
BCG in COVID-19. In this scenario, we need to rely on the results of BCG
trials before jumping to any conclusion. Hence, we strongly support

6. Recommendations
While preliminary data is indicative of the protective effects of BCG
on COVID-19 mortality, it is pertinent to wait until randomized trials are
completed. Of note, BCG vaccines are required in TB-endemic regions,
and their efficacy in COVID-19 is not certain. Consequently, the use of
BCG vaccines in COVID-19 may lead to shortages in supplies globally.
Additionally, the current data is observed at population levels, and the
lack of patient-level data incorporates confounders that may prematurely skew the findings in favor of BCG efficacy. BCG vaccines are
administered at birth in TB-endemic regions, and trained immunity may
not be immediately effective if BCG vaccines were administered to
prevent or manage COVID-19 among infected patients. Therefore, the
monitoring of protective outcomes in randomized control trials is
required before the BCG vaccine may be considered an important
strategy to combat COVID-19 and potential epidemics in the future.
7. Conclusion
BCG vaccination can broadly activate the human immune system to
better combat SARS-CoV-2, leading to decreased incidence and milder
courses, thereby reducing the burden on ICUs and hospital beds,
allowing for greater global productivity. We suggest future intradermal
and aerosolized investigations along with punch biopsies to evaluate
immune-histological changes to understand better the benefits provided
by BCG vaccination to vulnerable individuals and healthcare workers.
Further studies on the safety, tolerability, immunogenicity, and efficacy
of different administrative forms of BCG vaccination are recommended,
which would further help us solidify the understanding of this topic.
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[10] Riccò M, Gualerzi G, Ranzieri S, Bragazzi NL. Stop playing with data: there is no
sound evidence that Bacille Calmette-Guérin may avoid SARS-CoV-2 infection (for
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